MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag352

Медицинская библиотека · The oncologist · 2026

Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101).

Tanaka Takaaki, Makimoto Go, Nakamura Naoki, Kato Yuka, Oze Isao, Yokoyama Toshihide, Kuyama Shoichi, Senoo Satoru, Inoue Koji, Ichikawa Hirohisa, Maeda Yoshinobu, Togashi Yosuke, Hotta Katsuyuki

СтатьяКлиническое исследование II фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy.

MATERIALS AND

METHODS

In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for ≥4 courses of carboplatin plus PTX (≥150 mg/m²) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade ≥2 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (α = 0.10); a supportive stratified analysis accounted for the minimization factors.

RESULTS

Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade ≥2 CIPN occurred in 28.1% (9/32) of the GJG arm vs 51.5% (17/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P = .101). Grade 3-5 adverse-event incidence was similar between arms.

CONCLUSION

GJG was associated with fewer grade ≥2 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial.

CLINICAL TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials (jRCTs061210047).

Для цитирования: Tanaka Takaaki, Makimoto Go, Nakamura Naoki, Kato Yuka, Oze Isao, Yokoyama Toshihide, Kuyama Shoichi, Senoo Satoru, Inoue Koji, Ichikawa Hirohisa, Maeda Yoshinobu, Togashi Yosuke, Hotta Katsuyuki. Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101).. The oncologist. 2026. DOI: 10.1093/oncolo/oyag352.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.